Virpax hires New England Investors as out-licensing advisor for Envelta

Virpax Pharmaceuticals announced that the Company has engaged New England Investors to serve as the out-licensing advisor for Envelta in the People’s Republic of China. Envelta is Virpax’s non-opioid pain product candidate for acute and chronic pain including non-cancer pain. "We have engaged New England Investors, a life-sciences advisory firm, to represent us in our licensing efforts in China for Envelta," stated Anthony P. Mack, Chairman and CEO of Virpax Pharmaceuticals. "New England Investors has offices in the United States along with mainland China and Singapore. We believe that their China focus, along with their cross-border transactional experience in both pre-clinical and clinical pharmaceutical products, makes them an outstanding partner for us. "We believe that Virpax’s Envelta product under development for acute and chronic pain may be of interest to a number of Chinese pharmaceutical companies. The MET delivery system which crosses the blood brain barrier, is of special interest as it can potentially avoid the numerous side effects of pain medication currently in use."